U.S. Oil and Gas Stock News

Gibraltar Industries (ROCK) is back on investors’ radar after a recent share price move, with the stock closing at US$37.18 as its recent performance and fundamentals draw closer attention. See our latest analysis for Gibraltar Industries. The recent 4.61% 1 day share price return and 5.09% 7 day share price return sit against a much weaker backdrop, with the 1 year total shareholder return down 37.07% and the 5 year total shareholder return down 53.20%. This suggests that recent momentum is...

In May 2026, Valley National Bancorp completed a US$500.00 million fixed‑to‑floating subordinated notes offering, announced the full redemption of its US$300.00 million 3.00% subordinated notes due 2031, and affirmed a quarterly common dividend of US$0.1100 per share payable on July 1, 2026. Together with board approvals, director equity grants, and a refreshed corporate social responsibility report, these capital and governance moves outline how Valley is reshaping its funding mix while...

Earlier this week, East West Bancorp filed two shelf registrations totaling US$483.76 million for ESOP-related common stock offerings and granted routine stock awards to non-employee directors following its 2026 Annual Meeting. Shareholders also endorsed all governance proposals, including refreshed stock incentive and employee stock purchase plans, signaling strong support for management’s long-term capital and compensation framework. With shareholders backing new stock plans and...

Earlier in May 2026, UroGen Pharma reported new Phase 3 data showing UGN-103 achieved a 94.5% six-month durability of response in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, closely mirroring outcomes seen with its approved intravesical therapy ZUSDURI. The company also highlighted long-term durability results for ZUSDURI and outlined plans to file an NDA for UGN-103 in the third quarter of 2026, aiming to expand its RTGel-based bladder cancer franchise and...

Kymera Therapeutics (KYMR) is back in focus after showcasing expanded Phase 1b data for KT-621, its oral STAT6 degrader, at major dermatology and respiratory conferences. The company highlighted clinical signals in atopic dermatitis and asthma. See our latest analysis for Kymera Therapeutics. Despite the recent KT-621 data spotlight, Kymera Therapeutics’ share price has eased in the near term, with the 30 day share price return down 7.09% and the 90 day share price return down 10.79%. At the...

VinFast Auto (NasdaqGS:VFS) is back in focus after outlining plans to sell two factories in Vietnam to cut about US$6.9b of debt, alongside rolling out upgraded electric SUVs and expanding global after-sales support. See our latest analysis for VinFast Auto. The recent factory sale plan, upgraded VF 8 and VF 9 launches, and global service push arrive after a mixed run for investors. The share price is at US$3.57, with a 30 day share price return down 18.12%, a 90 day share price return up...

Earlier in May 2026, Mattel said it would lift spending by US$150,000,000 on mobile gaming, its Brick Shop initiative, and direct-to-consumer marketing, while simultaneously trimming its 2026 earnings-per-share guidance but committing to a US$1.50 billion share repurchase over three years. Alongside this heavier near-term investment, a cluster of routine director restricted stock unit settlements and a new Hot Wheels “Tiniest Team Principal” program highlight Mattel’s focus on both...

Earlier in May 2026, Skyward Specialty Insurance Group appointed industry veteran Melissa Goto as President of E&S Brokerage and Inland Marine and shareholders elected Peter C. Hearn to the board, adding deep underwriting and leadership expertise across complex specialty P&C markets. These leadership additions arrive as external analysts grow more optimistic about Skyward’s earnings outlook and its positioning in specialized commercial insurance niches. Next, we’ll explore how these analyst...

Anterix (ATEX) has drawn attention after recent trading, with the stock last closing at $63.57 and showing strong short term and past 3 months moves. This has prompted investors to reassess its current pricing. See our latest analysis for Anterix. Recent momentum has been strong, with a 30 day share price return of 40.73% and a year to date share price return of 185.96%. The 1 year total shareholder return of 134.58% points to sustained interest over a longer period. If this kind of move has...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Expedia...

It looks like Copa Holdings, S.A. ( NYSE:CPA ) is about to go ex-dividend in the next 4 days. Typically, the...

Earlier in May 2026, BeOne Medicines received U.S. FDA accelerated approval for BEQALZI (sonrotoclax), a next-generation BCL2 inhibitor for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies including a BTK inhibitor. This first U.S. approval for sonrotoclax reshapes BeOne’s oncology profile by adding a new commercial pillar alongside its BTK franchise and broad late-stage pipeline. We’ll now examine how adding BEQALZI as an approved BCL2...

Enovis (ENOV) has drawn attention after filing a US$92.16 million shelf registration to potentially issue up to 3,650,000 common shares in an employee stock ownership plan related offering. See our latest analysis for Enovis. The shelf registration and recent insider stock grants come as the share price trades at US$24.19, with a 90 day share price return of 7.89% but a 1 year total shareholder return that declined 23.35%. This indicates some recent momentum after a longer period of weaker...

In May 2026, Oruka Therapeutics reported a first-quarter net loss of US$31.82 million and disclosed insider stock option exercises and share sales by Senior Vice President Arjun Agarwal under a pre-arranged Rule 10b5-1 trading plan. Ahead of this, the company announced encouraging interim Phase 2a results for its ORKA-001 plaque psoriasis candidate and priced an upsized public offering of about US$700.40 million to support its development programs. Next, we’ll examine how the positive...

Kaiser Aluminum has recently benefited from stronger analyst sentiment and an improved earnings outlook, supported by industry-wide strength in aluminum amid supply disruptions and tariffs earlier this year. An interesting angle is that this improved outlook comes alongside signs of rich valuation metrics and recent insider selling, creating a complex setup for investors assessing the company’s current position. With analyst earnings expectations rising, we’ll now examine how this brighter...

It looks like First National Corporation ( NASDAQ:FXNC ) is about to go ex-dividend in the next 4 days. Typically, the...

Recent performance snapshot for STAAR Surgical STAAR Surgical (STAA) has drawn attention after a strong share price move, with the stock up about 26% over the past month and about 78% over the past 3 months. See our latest analysis for STAAR Surgical. At the current share price of US$32.47, STAAR Surgical’s recent 30 day share price return of 26.5% and 90 day share price return of 78.4% contrast with a 5 year total shareholder return that is down 77.8%, suggesting momentum has picked up after...

Zebra Technologies (ZBRA) has drawn fresh attention after raising its full year and second quarter sales growth guidance, alongside first quarter revenue of US$1,495 million and net income of US$135 million. See our latest analysis for Zebra Technologies. The guidance upgrade and recent earnings have contributed to a rebound in the share price, with a 1 month share price return of 12.23% and a 90 day gain of 10.47%. However, the 1 year total shareholder return is still down 10.08%, indicating...

Proto Labs (PRLB) drew fresh attention after reporting first quarter revenue growth of 10.4% year on year, along with EPS guidance for the upcoming quarter that came in ahead of analyst expectations. See our latest analysis for Proto Labs. The stock has responded positively around the earnings release, with a 1-month share price return of 10.43% and a year to date share price return of 38.97%. The 1-year total shareholder return of 93.81% points to strong recent momentum compared with a...

Teekay (TK) has moved back onto investor radars after reporting first quarter 2026 sales of US$286.09 million and net income of US$153.55 million, alongside a US$1.00 per share special dividend announcement. See our latest analysis for Teekay. The recent special dividend and first quarter earnings update come after a period of strong momentum, with a year to date share price return of 51.25% and a 1 year total shareholder return of 82.14%, suggesting improving sentiment around Teekay’s...

In May 2026, Coupang reported quarterly revenue growth but moved to a net loss, with adjusted EBITDA shrinking, prompting a Citi downgrade and coinciding with the announcement of a US$391 million stock repurchase plus an additional US$1.00 billion buyback authorization. A separate announcement highlighted how Coupang’s global logistics network helped a small U.S. salt producer, J.Q. Dickinson Salt-Works, access customers in more than 190 countries and regions, showcasing the company’s role...

In May 2026, Dana Incorporated reported past first-quarter 2026 results showing sales of US$1,868 million versus US$1,781 million a year earlier, with net income rising to US$1.09 billion from US$25 million, while still recording a basic loss per share of US$0.17 from continuing operations. The contrast between the very large net income and the loss per share from continuing operations suggests that one-off or non-core items played a major role in shaping overall profitability. We’ll now...

Why Pebblebrook’s preferred shares are drawing attention Recent analysis of Pebblebrook Hotel Trust (PEB) has focused on its Series G preferred shares, which are trading below liquidation value while offering a strong yield, supported by asset coverage and fixed charge coverage ratios. See our latest analysis for Pebblebrook Hotel Trust. PEB’s recent preferred share focus sits alongside a solid rebound in the common stock, with the share price up 20.36% over 90 days and a 67.22% total...